Anzeige
Mehr »
Mittwoch, 06.08.2025 - Börsentäglich über 12.000 News
Warum Guardian Metal die Pentagon-gestützte Antwort auf Chinas Dominanz ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
15 Leser
Artikel bewerten:
(0)

Endovascular Aneurysm Training Module Now Supports Vascutek's Anaconda' Devices

CLEVELAND, November 14, 2013 /PRNewswire/ --

Simbionix USA Corporation, the world's leading provider of medical simulation, training and education products, announces that it is increasing its library of training opportunities on the ANGIO Mentor'with the newEVAR Vascutek module.

(Logo: http://photos.prnewswire.com/prnh/20120502/529202-a )

The Simbionix ANGIO Mentor products are multidisciplinary surgical simulators that provide hands-on practice of endovascular procedures in a virtual reality simulated environment.

Abdominal Aortic Aneurysm (AAA) is defined as an increase of the abdominal aorta by at least 3 cm. In the USA, annual mortality from AAA rupture is approximately 15,000 patients, making it the 13th leading cause of death in the United States.

Traditional surgical treatment of AAA involves a large incision to place a synthetic graft to repair the diseased artery. This method may result in long hospital stays and painful recoveries. Physicians continue to seek less invasive alternatives to this major open surgical approach.

Today, more physicians are treating AAA using the Endovascular Aneurysm Repair (EVAR) approach which includes insertion of a synthetic graft via the femoral artery and placing it inside the aorta to repair the disease. The EVAR approach is also associated with a shorter hospital stay as well as reduced complications and mortality compared to the traditional surgical treatment. Despite that, it is still a very complicated procedure that requires advanced skills from surgeons.

Simbionix currently provides training tools and Virtual Reality (VR) simulators for most of the leading devices for EVAR procedures in the industry. Now, the EVAR Vascutek module will help physicians practice the clinical and practical aspects of Vascutek's Anaconda' stent graft system on various anatomies, using the latest techniques and therapeutic approaches available.

Paul Holbrook, President & CEO at Vascutek Ltd commented that "The endovascular abdominal aortic aneurysm training module for Anaconda' provides Vascutek with a specialized simulator enabling our dedicated team of Clinical Support Specialists to train clinicians worldwide on the deployment of the Anaconda' stent graft system. It also gives Vascutek the opportunity to further develop and enhance our clinician educational programs at international workshops and congresses. Simbionix have been very responsive to meeting the specific requirements of Vascutek offering a professional service at all times."

"Understanding the important role simulation plays in training physicians on the use of various medical devices, Simbionix has always made a point of working in partnership with leading device manufacturers to provide the most realistic hands-on products," said Simbionix President, Mr. Ran Bronstein. "This goes hand in hand with our goal- To Advance Clinical Performance- as it has been proven that learning and practicing procedures on the ANGIO Mentor shortens the learning curve and helps surgeons keep up with the ongoing improvements in medical technologies."

To experience the EVAR Vascutek module hands-on, visit Vascutek's booth at the VeithSymposium, November 19-23, 2013 in New York, USA.

Simbionix USA Corporation is the world's leading provider of simulation, training and education products for medical professionals and the healthcare industry. The company is committed to delivering high quality products, advancing clinical performance and optimising procedural outcomes.

Visit: http://www.vascutek.com http://www.simbionix.comFacebook,Twitter andLinkedIn.

Contact: Rebecca Levy, Manager of Marketing Communications, at rebecca@simbionix.com, +1-216-2292040.

SOURCE Simbionix Ltd.

© 2013 PR Newswire
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.